Biocon-Mylan collaboration drug portfolio worth $33 bn

Biocon in an investor presentation has revealed that it is sitting on a potential $33 billion portfolio of biosimilar drugs that will expire by 2015

The two companies are planning to come out with biosimilars such as "Trastuzumab, Peg-filgrastim, Bevacizumab, Adalimumab and Eternacept", which could be used in treating various ailments including cancer and psoriasis.
http://www.business-standard.com/india/news/biocon-mylan-collaboration-drug-portfolio-worth-33-bn/164500/on